Expanding treatments for lower urinary tract symptoms, secondary to benign prostatic enlargement. A capacity and budget impact analysis in four Nordic countries
DOI:
https://doi.org/10.2340/sju.v60.44243Keywords:
Benign prostatic enlargement, benign prostate hyperplasia, minimally invasive surgical treatments, laser enucleation of the prostate, capacity impact, cost analysis, budget impactAbstract
Objectives: This capacity and budget impact analysis considers implications of offering a more diversified benign prostate enlargement (BPE) surgical care offering from a healthcare payer perspective in Sweden, Denmark, Norway and Finland.
Methods: A cohort simulation model compares 4-year treatment costs and capacity impact, including hospital bed-days and operating time, with Transurethral Resection of the Prostate (TURP), Holmium Laser Enucleation of the Prostate (HoLEP) using MOSES™Technology, photoselective vaporisation of the prostate (PVP) and Rezūm™ Water Vapour Therapy (WVTT). Current treatment choice is compared to a hypothetical scenario, where TURP-proportion is reduced to 50% and volumes of HoLEP, PVP and WVTT are increased. Deterministic sensitivity analysis (DSA) and probabilistic sensitivity analysis (PSA) considered uncertainty when varying all model inputs individually and simultaneously.
Results: Reducing the proportion of TURP to 50% and shifting towards a more diversified surgical offering could save 590 bed-days, 2,281 theatre hours and SEK 14,020,153 in Sweden; 343 bed-days, 1,248 theatre hours and DKK 10,493,266 in Denmark; 267 bed-days, 1,032 theatre hours and NOK 9,329,844 in Norway and 576 bed-days, 1,181 theatre hours and 1,059,528€ in Finland per year. WVTT emerged as the lowest-cost procedure in all scenarios. Both DSAs and PSAs demonstrated outcome robustness.
Conclusion: The adoption of a more diversified surgical care offering for patients with BPE in the Nordics may free theatre time and hospital bed-days and create meaningful cost-savings, which off-set higher initial device cost. Economic considerations should not constitute a barrier to the adoption of a patient-centric surgical care offering for BPE patients in the Nordics.
Downloads
References
Stranne J, Damber J-E, Fall M, et al. One-third of the Swedish male population over 50 years of age suffers from lower urinary tract symptoms. Scand J Urol Nephrol. 2009;43(3):199–205. https://doi.org/10.1080/00365590902833747 DOI: https://doi.org/10.1080/00365590902833747
Andersson SO, Rashidkhani B, Karlberg L, et al. Prevalence of lower urinary tract symptoms in men aged 45–79 years: a population‐based study of 40 000 Swedish men. BJU Int. 2004;94(3):327–331. https://doi.org/10.1111/j.1464-410X.2004.04930.x DOI: https://doi.org/10.1111/j.1464-410X.2004.04930.x
Miernik A, Fritzsche J, Libutzki B, et al. Real-world data and treatment patterns of patients with lower urinary tract symptoms due to benign prostatic hyperplasia in Germany: an observational study using health insurance claims data. World J Urol. 2021;39:4381–4388. https://doi.org/10.1007/s00345-021-03787-2 DOI: https://doi.org/10.1007/s00345-021-03787-2
Oelke M, Bachmann A, Descazeaud A, et al. EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol. 2013;64(1):118–140. https://doi.org/10.1016/j.eururo.2013.03.004 DOI: https://doi.org/10.1016/j.eururo.2013.03.004
Gravas S, Gacci M, Gratzke C, et al. Summary paper on the 2023 European Association of Urology guidelines on the management of non-neurogenic male lower urinary tract symptoms. Eur Urol. 2023;84(2):207–222. https://doi.org/10.1016/j.eururo.2023.04.008 DOI: https://doi.org/10.1016/j.eururo.2023.04.008
Gravas S, Malde S, Cornu J-N, et al. From BPH to male LUTS: a 20-year journey of the EAU guidelines. Prostate Cancer Prostatic Dis. 2024;27(1):48–53. https://doi.org/10.1038/s41391-023-00700-3 DOI: https://doi.org/10.1038/s41391-023-00700-3
Turney B, Wetterauer C, Sato R, et al. Changing trends in the surgical management of BPO in Europe. Eur Urol. 2024;85:S901. https://doi.org/10.1016/S0302-2838(24)00745-0 DOI: https://doi.org/10.1016/S0302-2838(24)00745-0
Landspatientregisteret: Avanceret udtræk [Internet]. Sundhetsdata-Styrelsen; 2024. Available from: https://www.esundhed.dk/Emner/Operationer-og-diagnoser/Landspatientregisteret-Avanceret-udtraek#tabpanelFE2A577AEAAA41EE88D48460C9B1A8DD
Toimenpiteiden lukumäärä vuosittain – THL kuutio- ja tiivistekäyttöliittymä. 2024.
Helsedirektoratet. Aktivitet i somatiske sykehus, spesialisthelsetjenesten. Folkehelseinstituttet, Oslo:2024.
Statistikområden. Statistical database. Dödsorsaker. Stockholm: Socialstyrelsen; 2024.
Rezum for treating lower urinary tract symptoms secondary to benign prostatic hyperplasia. [Medical Technology Guidance MTG49]. Na-tional Institute of Health and Care Excellence, London.
Lourenco T, Armstrong N, N’dow J, et al. Systematic review and economic modelling of effectiveness and cost utility of surgical treatments for men with benign prostatic enlargement. Health Technol Assess. 2008;12(35):1–146. https://doi.org/10.3310/hta12350 DOI: https://doi.org/10.3310/hta12350
Rosen R, Altwein J, Boyle P, et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol. 2003;44(6):637–649. https://doi.org/10.1016/j.eururo.2003.08.015 DOI: https://doi.org/10.1016/j.eururo.2003.08.015
Eredics K, Wachabauer D, Röthlin F, et al. Reoperation rates and mortality after transurethral and open prostatectomy in a long-term nationwide analysis: have we improved over a decade? Urology. 2018;118:152–157. https://doi.org/10.1016/j.urology.2018.04.032 DOI: https://doi.org/10.1016/j.urology.2018.04.032
Alexander CE, Scullion MM, Omar MI, et al. Bipolar versus monopolar transurethral resection of the prostate for lower urinary tract symptoms secondary to benign prostatic obstruction. Cochrane Database Syst Rev. 2019;12:CD009629. https://doi.org/10.1002/14651858.CD009629.pub4 DOI: https://doi.org/10.1002/14651858.CD009629.pub4
Bachmann A, Tubaro A, Barber N, et al. A European multicenter randomized noninferiority trial comparing 180 W GreenLight XPS laser vaporization and transurethral resection of the prostate for the treatment of benign prostatic obstruction: 12-month results of the GOLI-ATH study. J Urol. 2015;193(2):570–578. https://doi.org/10.1016/j.juro.2014.09.001 DOI: https://doi.org/10.1016/j.juro.2014.09.001
Yilmaz M, Karaaslan M, Aybal HC, et al. Laser enucleation of the prostate in men with very large glands≥ 175 ml: a systematic review. Ann Med Surg. 2022;80:104279. https://doi.org/10.1016/j.amsu.2022.104279 DOI: https://doi.org/10.1016/j.amsu.2022.104279
McVary KT, Gittelman MC, Goldberg KA, et al. Final 5-year outcomes of the multicenter randomized sham-controlled trial of a water va-por thermal therapy for treatment of moderate to severe lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol. 2021;206(3):715–724. https://doi.org/10.1097/JU.0000000000001778 DOI: https://doi.org/10.1097/JU.0000000000001778
Cornu J-N, Ahyai S, Bachmann A, et al. A systematic review and meta-analysis of functional outcomes and complications following tran-surethral procedures for lower urinary tract symptoms resulting from benign prostatic obstruction: an update. Eur Urol. 2015;67(6):1066–1096. https://doi.org/10.1016/j.eururo.2014.06.017 DOI: https://doi.org/10.1016/j.eururo.2014.06.017
Kavoussi NL, Nimmagadda N, Robles J, et al. MOSESTM technology for holmium laser enucleation of the prostate: a prospective double-blind randomized controlled trial. J Urol. 2021;206(1):104–108. https://doi.org/10.1097/JU.0000000000001693 DOI: https://doi.org/10.1097/JU.0000000000001693
McVary KT, Gange SN, Gittelman MC, et al. Minimally invasive prostate convective water vapor energy ablation: a multicenter, random-ized, controlled study for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol. 2016;195(5):1529–1538. https://doi.org/10.1016/j.juro.2015.10.181 DOI: https://doi.org/10.1016/j.juro.2015.10.181
Roehrborn CG, Gange SN, Gittelman MC, et al. Convective thermal therapy: durable 2-year results of randomized controlled and prospec-tive crossover studies for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. J Urol. 2017;197(6):1507–1516. https://doi.org/10.1016/j.juro.2016.12.045 DOI: https://doi.org/10.1016/j.juro.2016.12.045
Gauhar V, Gilling P, Pirola GM, et al. Does MOSES technology enhance the efficiency and outcomes of standard holmium laser enucleation of the prostate? Results of a systematic review and meta-analysis of comparative studies. Eur Urol Focus. 2022;8(5):1362–1369. https://doi.org/10.1016/j.euf.2022.01.013 DOI: https://doi.org/10.1016/j.euf.2022.01.013
Yin L, Teng J, Huang C-J, et al. Holmium laser enucleation of the prostate versus transurethral resection of the prostate: a systematic re-view and meta-analysis of randomized controlled trials. J Endourol. 2013;27(5):604–611. https://doi.org/10.1089/end.2012.0505 DOI: https://doi.org/10.1089/end.2012.0505
Miner M, Rosenberg MT, Perelman MA. Treatment of lower urinary tract symptoms in benign prostatic hyperplasia and its impact on sexual function. Clin Therap. 2006;28(1):13–25. https://doi.org/10.1016/j.clinthera.2006.01.004 DOI: https://doi.org/10.1016/j.clinthera.2006.01.004
Komura K, Inamoto T, Takai T, et al. Incidence of urethral stricture after bipolar transurethral resection of the prostate using TUR is: Re-sults from a randomised trial. BJU Int. 2015;115(4):644–652. https://doi.org/10.1111/bju.12831 DOI: https://doi.org/10.1111/bju.12831
Bachmann A, Tubaro A, Barber N, et al. 180-W XPS GreenLight laser vaporisation versus transurethral resection of the prostate for the treatment of benign prostatic obstruction: 6-month safety and efficacy results of a European Multicentre Randomised Trial—the GOLIATH study. Eur Urol. 2014;65(5):931–942. https://doi.org/10.1016/j.eururo.2013.10.040 DOI: https://doi.org/10.1016/j.eururo.2013.10.040
Johnston M, Shah T, Emara A, et al. MP01-03 Rezūm water vapour ablation therapy for benign prostatic hyperplasia: initial results from the United Kingdom. J Urol. 2019;201:e1–e2. https://doi.org/10.1097/01.JU.0000554867.66478.23 DOI: https://doi.org/10.1097/01.JU.0000554867.66478.23
Qiu T, Aballéa S, Pochopień, M, et al. A systematic review on the appropriate discounting rates for the economic evaluation of gene ther-apies: whether a specific approach is justified to tackle the challenges? Int J Technol Assess Health Care. 2024;40(1):e23. https://doi.org/10.1017/S0266462324000096 DOI: https://doi.org/10.1017/S0266462324000096
Salmivalli A, Boström P, Nurminen P, et al. National trends of surgery for benign prostatic hyperplasia in Finland. Scand J Urol. 2024;59:70–75. https://doi.org/10.2340/sju.v59.32425 DOI: https://doi.org/10.2340/sju.v59.32425
Solholm V. Komplikasjoner og liggetid etter urologisk kirurgi. 2016.
Sagen E, Javid R, Liivrand L, et al. Patient related factors affecting in-hospital costs of a TURP procedure. Scand J Urol. 2021;55(4):324–330. https://doi.org/10.1080/21681805.2021.1893380 DOI: https://doi.org/10.1080/21681805.2021.1893380
Sundhetstyrelsen. Dagkirurgi i Danmark, Status og udviklingsmuligheder. E.F. SYGEHUSE, Copenhagen.
Forsmark A, Gehrman J, Angenete E, et al. Health economic analysis of open and robot-assisted laparoscopic surgery for prostate cancer within the prospective multicentre LAPPRO trial. Eur Urol. 2018;74(6):816–824. https://doi.org/10.1016/j.eururo.2018.07.038 DOI: https://doi.org/10.1016/j.eururo.2018.07.038
XprESS multi sinus dilation system for treating chronic sinusitis. Sodra Regionvardsnamnden. Medical technologies guidance [MTG30], Lund 2016.
The PLASMA system for transurethral resection and haemostasis of the prostate. NICE National Institute of Health and Care Excellence; London, UK: 2021.
Regionala priser och ersättningar för södra Sjukvårdsregionen. Sodra Regionvardsnamnden: 2020.
Gilpin L, Zekan D, Baugh B, et al. Evaluating the efficacy of employing local anesthetic prostatic blocks during Rezum procedure. Cureus. 2022;14(9):e29598. https://doi.org/10.7759/cureus.29598 DOI: https://doi.org/10.7759/cureus.29598
Khadhouri S, Guillaumier S, Drummond L, et al. Feasibility of outpatient daycase local anaesthestic Rezūm™ without sedation. BMC Urol. 2024;24(1):80. https://doi.org/10.1186/s12894-024-01471-2 DOI: https://doi.org/10.1186/s12894-024-01471-2
Wahba R, Urbanski A, Datta R, et al. Operating room time savings in Germany-and UK-based hospitals with 3D-VS. 2D-imaging technology in laparoscopic surgery: Meta analysis and budget impact model–Health economic evaluation. Int J Surg. 2022;102:106643. https://doi.org/10.1016/j.ijsu.2022.106643 DOI: https://doi.org/10.1016/j.ijsu.2022.106643
InEK Datenbrowser. Datenjahr 2023, I.f.d.E.i.K. (InEK), Editor. Institut für das Entgeltsystem im Krankenhaus (InEK), Siegburg, Germany.
Additional Files
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Deirdre Blissett, Erik Sagen, Espen Kvan, Vasileios Souvleros, Dimitri Pogodin-Hannolainen, Amanda Spies, Laura Bruno
This work is licensed under a Creative Commons Attribution 4.0 International License.
As from Volume 59 (2024) all published articles, unless otherwise specified, are published under CC-BY license, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, with the condition of proper attribution to the original work.
